47P - Efficacy and safety of cadonilimab-based therapies in non-small cell lung cancer patients with progression after immunotherapy

Background

Immunotherapy has improved outcomes for patients with non-small cell lung cancer (NSCLC), but progression after immunotherapy remains a significant clinical challenge. Cadonilimab offers a promising strategy to overcome this problem. This study evaluates the efficacy and safety of cadonilimab in patients with unresectable locally advanced or advanced NSCLC who have progressed following prior immunotherapy.

Methods

This retrospective study evaluated 70 patients with unresectable locally advanced or advanced NSCLC treated with cadonilimab alone or combined with the chemotherapy/anti-angiogenic therapy. Adverse events and patient responses were assessed using Common Terminology Criteria for Adverse Events v5.0 and Response Evaluation Criteria for Solid Tumors v1.1.

Results

The objective response rate (ORR)was observed in 15 out of 70 (21.43%) patients, and the disease control rate was 74.29% (52/70). No patient achieved a complete response. The median progression-free survival (mPFS) was 2.23 months (95% CI: 1.87–2.93). Patients given the combination of anti-angiogenic therapy had higher ORR (29.55% vs. 7.69%, p=0.031) and prolonged mPFS (2.47 vs. 1.87 months, p=0.022). Additionally, patients with a prior benefit from immunotherapy showed significantly improved ORR (30.23% vs. 11.11%, p=0.044) and mPFS (2.90 vs. 1.70 months, p=0.015) when treated with cadonilimab.

Treatment efficacy of different system agents

Conclusions

The combination of cadonilimab with anti-angiogenic therapy exhibits synergistic anti-tumor activity, and cadonilimab-based treatments demonstrate enhanced efficacy, particularly in patients with prior benefit from immunotherapy.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.